Skip to content
DataLookout
Menu

ESTROTIMPNCT05486182

Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer

StatusCompleted
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed
  2. Minor Primary completion date changed from estimate of Feb 2025 to Apr 18, 2025
    • Study completion date: Dec 2025 to Jan 2026
    v5
  3. Notable Lead sponsor: Zionexa to GE Healthcarev4 Show 6 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 152 to confirmed 153
    • Study sites: 9 to 11
    • Primary completion date: Dec 2024 to Feb 2025
    • Study completion date: Jun 2025 to Dec 2025
    • Collaborators: 3 to 2
  4. Notable Eligibility criteria expanded, about 34 words
    • Study sites: 6 to 9
    v3
  5. Minor Study sites: 1 to 6v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To assess the impact of ESTROTEP PET/CT on metastatic breast cancer patients management, initially ER+ and HER2-, in relapse after first-line treatment combining hormone therapy.
Timeframe: Change from baseline therapeutic measure at 15 days after ESTROTEP PET/CT

Arms and interventions

Prospective populationExperimental

Drugs: 18F Fluoroestradiol Radiopharmaceutical with PET/CT

Sites

11 sites in 1 country